08:00 , Jan 7, 2013 |  BioCentury  |  Emerging Company Profile

MinervaX: More with less in GBS

MinervaX ApS has developed a vaccine that uses a single fusion protein to trigger an immune response that could target more than 95% of Group B Streptococcusstrains. The preclinical candidate could provide greater protection than...
07:00 , Jun 2, 2011 |  BC Innovations  |  Targets & Mechanisms

Getting at the crux of the antigen

Novartis AG researchers have used structure-based antigen design to rationally optimize vaccines for respiratory syncytial virus1 and Group BStreptococcus.2 Although the strategy itself is not new, thework serves as proof of conceptfor its application to...